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1122B-35 Prevalence of Intlmal CRP in Unstable Angina 
Atheroms: Modification by Statin Therapy 
Gerhard Bauriedel. Rend Andri6, Dirk Skowasch, Peter Braun, Thomas M. Schiele, 
Berndt L(Jderitz, Department of Cardiology, University of Bonn, Bonn, Germany, 
Department of Cardiology, Heart Center, Duisburg, Germany. 
Background: Inflammation is basically involved in progression and/or complication of ath- 
erosclerosis. Though C-reactive protein (CRP) is an independent serum marker strongly 
predicting major adverse coronary events, the intimal prevalence of CRP in advanced 
target lesions that determine different clinical settings, and its modification by statin ther- 
apy, are unknown. 
Methods : Coronary atherectomy samples retneved from 48 primary target lesions of 
patients suffering either unstable angina (UA; n=32) or stable angina (SA; n=16) were 
examined by immunohistochemistry using the APAAP technique. Presence of CRP, 
plaque localization and prevalence in either group were studied. 
Results: Immunhistochemical examination demonstrated signals for CRP in 27 of 48 
(56%) coronary target lesions vs. none of 20 undiseased control samples~ As the central 
finding, immunoreactive CRP was detected in 23 of 32 (72%) UA lesions, and only in 4 of 
16 (27%) SA lesions (p<0.01). Lesional CRP-positive ceils correlated strongly with 
plaque areas exhibiting ruptures and fissures (r=0.86, p<0,001), with a local expression 
up to 70%, and were identified as macrophages/foam cells by double immunostaining for 
CRP and CD68. When catagorizing all lesions into those with and without statin therapy, 
CRP was found consistently decreased in lesions from patients with statin medication 
(30 vs. 75%; p<0.01), the more with UA lesions. 
Conclusions: Intimal CRP shows a strong prevalence in clinical unstability, indicating an 
important stimulus for foam cell formation and plaque rupture. Beyond lipid lowering, 
plaque stabilization via reduction of infimal CRP may be a new important herapeutic 
effect of statins preventing plaque rupture. 
1122B-36 Enhanced Expression of Lectin-Like Oxidized Low 
Density Lipoproteln Receptor (LOX-1) at Sites of the 
Culprit Lesion in Patients With Acute Coronary 
Syndromes 
Yuii Sakanoue, Takahiko Naruko, Kazuo Haze, Masato Otsuka, Akira Itoh, Masayuki 
Ogami, Yoshihiro Ikura, Masahiko Ohsawa, Makiko Ueda, Osaka City General Hospital, 
Osaka, Japan, Osaka City University Medical School, Osaka, Japan. 
Background: Experimental studies have shown that oxidized low density lipoprotain (OX- 
LDL) plays an important role in the progression of atherosclerosis. Recently, we have 
demonstrated that ox-LDL play a pivotal role in the genesis of coronary plaque instability 
and the development of acute coronary syndromes. (Ehara Set al, Circulation 103,1955- 
1960,2001). Lectin-like oxidized low-density lipoprotein receptor (LOX-1) is also consid- 
ered to play a key role in atherogenesis, and recent in vitro studies have demonstrated 
that LOX-1 binds to activated platelets. Thus far, we are unaware of any studies that 
have looked into the potential role of LOX-1 in patients with acute coronary syndromes. 
For this reason, we have studied the expression of LOX-1 in various types of human cor- 
onary atherosclerotic lesions including ruptured and eroded plaques. Methods: Frozen 
sections of normal coronary artery segments (Normal, n=21), and coronary atheroscle- 
rotic segments (n=7f) with early atherosclerotic plaques (eady AP), advanced atheroma- 
tous plaques (advanced AP), ruptured plaques (RP), and eroded plaques (EP) were 
stained with antibodies against smooth muscle cells (SMC), macrophages (MAC), endot- 
helial cells (EC), platelets (GPIIb/llla), and LOX-1. We used computer-aided planimetry 
which quantified the immunoreactivity of LOX-1 and MAC. For the identification of cell 
types which express LOX-1, immunodouble staining was also used. Results: In Normal, 
there was no expression of LOX-I. In early AP, LOX-1 expression was found in EC and 
SMC at the plaque site. In advanced AP, LOX-1 expression was found in accumulated 
MAC and also EC of intraplaque microvessels. In RP and EP, LOX-1 was strongly 
expressed not only in MAC, but also in GPIIb/llla-positive platalet hrombus, and EC of 
intraplaque microvessels. The percentage of LOX-1 positive area within the intima was 
significantly higher in EP (p< 0.01) and RP (p<0.004) than in advanced AP. Conclu- 
sions: These findings strongly suggest a role for LOX-1 in macrophage infiltration and in 
thrombosis with activated platelets, which may be integral parts of inflammatory 
response related to plaque rupture and erosion in human coronary atherosclerotic 
lesions. 
1122B-37 Carotid Atherosclerotic Plaque Instability in Patients 
With Acute Myocardial Infarction 
Andrea Rossi. Lorenzo Franceschini, Massimiliano Fusaro, Giorgio Golia, Piero Zardini, 
Divisione di Cardiologia, Verona, Italy, 
The instability of the atheroscterotic plaque (PL) is partly determined by local factors, but 
systemic factors such as infection, inflammation, autoimmunity or genes might also be 
important. We aimed to analyze whether patients with acute coronary artery event (ACE) 
such as myocardial infarction (AMI) might have a higher proportion of unstable PL of 
carotid arteries compared with patients without clinically evident ACE. Methods: 69 con- 
secutive patients with AMI (Group 1) and 95 patients without ACE (Group 2) had carotid 
arteries duplex ultrasounds. Carotid atherosclerosis has been quantified by: number of 
PL, intimal thickening and degree of maximal stenosis. According their morphology, PL 
were divided in stable (fibrocalcific) and unstable (soft and or not-homogeneous). 
ResultS: The two groups did not differ for age (66+8 vs 68±19; p=0.3), sex (9% vs 22%; 
p=0.3), number of carotid PL (2.8+1 vs 2.6:I:2; p=0.2), degree of stenosis (59±2% vs 
36±3%; p=0.2)and intimal thickening (1.04±0.2 vs 1.06i-0.2; p=0.8), but group 1 had 
more frequently carotid unstable PL compared with group 2 (43% vs 15%; p=0.004), a 
higher number of carotid unstable PL (0.51~).6 vs 0.16+0.4: p<0.0001). In the overall 
population, logistic regression analysis showed that presence of ACE, adjusted for tradi- 
tional vascular risk factors predicted the presence of unstable carotid PL (4.5; 95% C.I.: 
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2.1-9.3; p<0.0001). Conclusion: Patients with ACE had frequently unstable PL in other 
arterial sites such as carotid arteries. This findings supports the hypothesis that PL insta- 
bility might partly reflect a sistemic process. 
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1123-38 Early and Late Results of Thrombectomy Prior to 
Stenting in Acute Myocardial Infarction: Principal 
Report of the EndiCOR X-SlZER AMI Registry 
David A. Cox. Thomas Stuckey, Joseph Babb, Reggie Low, Louis Cannon, Robert 
Iwaoka, Mark Turco, Bruce Brodie, Alexandra Lansky, Gregg W. Stone, Mid Carolina 
Cardiology, Charlotte, North Caro/ina, The Cardiovascular Research Foundation, New 
York City, New York. 
Background: Stenting thrombotic lesions in AMI may result in distal embolization, 
reduced TIMI flow, and microvascular obstruction. The EndiCOR X-SIZER is a simple-to- 
use, percutaneous thrombectomy catheter employing a distal helical cutter with vacuum- 
assisted debris removal which may facilitate restoration of normal myocardial perfusion 
after AMI intervention. 
Methods: To examine the safety and utility of the X-SIZER prior to stent implantation, 
212 consecutive pts presenting within 24 hours of AMI were enrolled in a multicenter, 
prospective registry of X-SIZER thrombectomy prior to stenting. Pts undergoing primary 
stenting as well as rescue stenting for failed thrombolysis were included. End organ per- 
fusion was assessed by the myocardial blush score by an independent core anglo- 
graphic laboratory. 
Results: The mean age was 59.2 yrs; 73.6% were male; and 15.2% had diabetes. GP 
2b3a inhibitors were used in 86% of pts. The infarct artery was the RCA in 46%, LAD 
32%, LCX 12%, and SVG in 10%. By core lab analysis, 57% of pts had TIMI 0-1 flow on 
initial angiogram, 17% had TIMI 2 flow, and 26% had TIMI-3 flow. The X-SIZER success- 
fully accessed the lesion in 93% of patients. TIMI-3 flow was achieved in 81% of patients 
after thrombectomy and 91% after stenting. Thrombus burden was reduced with the 
device from 29.6 mm 2 to 6.3mm 2 and then to 1.7 mm 2 with adjunctive stanting. Normal 
(grade 3) myocardial blush was obtained in 52.3% of all patients, and 56% of pts with 
TIMI-3 flow. One month adverse events included cardiac death in 3.3% of pts, reinfarc- 
tion in 1.9%, TVR in 3.3%, emergent CABG in 0.9%, and any MACE in 6.6% of pts. 
Conclusion: Adjunctive thrombectomy with the EndiCOR X-SIZER before stanting for 
AMI is safe and effectively removes thrombus. Normal myocardial perfusion as evi- 
denced by a blush score of 3 was restored in 52.3% of patients, significantly improved 
compared to prior reports of primary and rescue PCI in which blush socres of only 19- 
28% have been reported. Six month follow-up will be available by March 2002. Based on 
these data, a large scale, randomized trial of X-SIZER thrombectomy in AMI is planned. 
1123-39 Stenting in Acute Myocardial Infarction: Restanoeis Is 
Primarily Caused by Stent Underexpansion 
Arnd Schaefer, Dieter Fischer, Gerd P. Meyer, Gunnar Klein, Peter Lippolt, Dirk 
Hausmann, Medical Schoo/ Hannover, Hannover, Germany. 
Background: Pdmary angioplasty (PA) with stenting is an alternative to thrombolysis for 
acute myocardial infarction (AMI). The mechanism of restenosis after stenting in this set- 
ting, however, is poorly understood 
Methods: We performed intravascular ultrasound (IVUS, Endosonics, motorized pull- 
back O,5mm/sac) in 35 patients (41 stants) 6-months after PA for AMI (NTG during stent- 
ing). The ideal lumen was calculated by a trendline based on the proximal and distal 
reference lumen (4 ram). Within the stent, the area bordered by the stent struts (stent 
area) and the lumen area were calculated. The relative contribution of stent underexpan- 
sion and neointima formation to lumen narrowing in the stent (compared to the ideal 
lumen area) was calculated. 
Results: At 6 months follow-up mean, maximal and minimal narrowing were 26%, 40% 
and 15%. Relative reduction caused by Neointima formation 33%, 43% and 16% LN, 
stent underexpansion caused 67%, 57 % and 84%. 
Conclusions: Lumen narrowing after stenting for AMI is primarily caused by stent under- 
expansion and not by neointima formation. Modification of stenting techniques in the set- 
ting of AM1 may be required. 
